Tag Archives: ITRM

Iterum Therapeutics (ITRM) Gets a Buy Rating from Needham

In a report released today, Alan Carr from Needham assigned a Buy rating to Iterum Therapeutics (ITRM – Research Report), with a price target of $7.00. The company’s shares closed last Thursday at $3.50. According to TipRanks.com, Carr is a

RBC Capital Reiterates Outperform on Iterum Therapeutics Shares, Sees 132% Upside For The Stock

In a research report issued on Tuesday, RBC Capital analyst Gregory Renza reiterated an Outperform rating on Iterum Therapeutics (NASDAQ:ITRM)with a price target of $8, which represents a potential upside of 132% from where the stock is currently trading. According

Analysts Are Bullish on These Healthcare Stocks: Iterum Therapeutics (ITRM), Pluristem (PSTI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iterum Therapeutics (ITRM – Research Report) and Pluristem (PSTI – Research Report) with bullish sentiments. Iterum Therapeutics (ITRM) In a report released

H.C. Wainwright Remains a Buy on Iterum Therapeutics Plc (ITRM)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Iterum Therapeutics Plc (ITRM – Research Report) today and set a price target of $17. The company’s shares closed last Monday at $6.81. According to TipRanks.com, Arce is a 4-star

H.C. Wainwright Initiates a Buy Rating on Iterum Therapeutics Plc (ITRM)

In a report released today, Ed Arce from H.C. Wainwright initiated coverage with a Buy rating on Iterum Therapeutics Plc (ITRM – Research Report) and a price target of $17. The company’s shares closed yesterday at $6.60. Arce commented: “Valuation

Needham Sticks to Its Buy Rating for Iterum Therapeutics Plc (ITRM)

Needham analyst Alan Carr maintained a Buy rating on Iterum Therapeutics Plc (ITRM – Research Report) today and set a price target of $20. The company’s shares opened today at $7.02. Carr said: “Iterum reported 4Q18 financial results today. Mgmt